Trophos

Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.

Trophos
TypePrivately held company
FateAcquired by Hoffmann-La Roche
FoundedMarseille, France (1999 (1999))
Founder
  • Christopher Henderson
  • Olivier Pourquie
  • Jean-Louis Kraus
  • Antoine Beret
  • Michel Delaage
Defunct2015 (2015)
Headquarters
France 

Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622).[1][2] Olesoxime is a mitochondrial targeted compound, which is a member of a new class of therapeutic agents aimed at bringing significant therapeutic benefit to patients suffering from devastating neurological diseases.[3][4]

Results from an international, double-blind, placebo-controlled phase II study involving 165 type II and non-ambulatory type III patients with spinal muscular atrophy, completed in February 2014 to assess safety and efficacy of olesoxime (TRO19622) showed that patients treated with olesoxime were able to maintain motor function over the two-year period of the study and that typical health complications associated with SMA occurred less frequently than in patients treated with a placebo, leading to better well being.[5]

In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for €120,000,000 upfront and up to €350,000,000 in milestone performance payments.[6][7] The deal was completed shortly afterwards.

References
  1. Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A. S.; Covey, D. F.; Ostuni, M. A.; Lacapere, J.-J.; Massaad, C.; Schumacher, M.; Steidl, E.-M.; Maux, D.; Delaage, M.; Henderson, C. E.; Pruss, R. M. (2007). "Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis". Journal of Pharmacology and Experimental Therapeutics. 322 (2): 709. doi:10.1124/jpet.107.123000. PMID 17496168.
  2. "olesoxime". UKMi New Drugs Online Database. Retrieved 2 January 2016.
  3. "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrials.gov. 5 February 2010. Retrieved 3 October 2010.
  4. "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrials.gov. May 2010. Retrieved 3 October 2010.
  5. "Trophos will present results of pivotal phase II/III study of olesoxime in spinal muscular atrophy patients at the American Academy of Neurology (AAN)" (Press release). Trophos. 29 April 2014 – via AFM-Telethon.
  6. Franklin, Joshua (16 January 2015). "Roche buys France's Trophos to expand in neuromuscular disease". Reuters. Retrieved 30 December 2015.
  7. Staff (15 February 2015). "Roche to Buy Trophos for Up-to-$543M". Genetic Engineering & Biotechnology News (paper). 35 (4). p. 6.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.